Navigation Links
Best Antidepressant May Depend on Patient: Study
Date:12/6/2011

By Amanda Gardner
HealthDay Reporter

MONDAY, Dec. 5 (HealthDay News) -- Newer antidepressants seem to be about as effective as one another, a new analysis indicates.

This suggests that the choice of which drug is appropriate for which patient should be made on the basis of such considerations as side effects, cost and patient preference.

"They're all equally effective," said Dr. David Schlager, a clinical assistant professor of psychiatry and behavioral science at Texas A&M Health Science Center College of Medicine.

"They're interchangeable except for side effects," he added, so psychiatrists do tend to "exploit the side-effect profile" to find suitable medications for individual patients, he added.

According to the background information in the new study, appearing in the Dec. 6 issue of Annals of Internal Medicine, some 27 million people in the United States had taken antidepressants as of 2005.

Most of these drugs are "second-generation" medications such as selective serotonin reuptake inhibitors (SSRIs), norepinephrine reuptake inhibitors (SNRIs) and related drugs.

SSRIs include the best-selling Prozac (fluoxetine) and Zoloft (sertraline). An example of an SNRI is Effexor (venlafaxine).

Led by Dr. Gerald Gartlehner, the analysis was funded primarily by the U.S. Agency for Healthcare Research and Quality.

Authors reviewed data from 234 previously published studies, all of them randomized trials that had included at least 1,000 participants each.

While there was no difference in drug effectiveness, there were distinctions in how quickly a drug took effect, side effects and quality of life.

For instance, the authors said, Remeron (mirtazapine) takes effect faster than Prozac, Zoloft, Paxil (paroxetine) or Celexa (citalopram).

Bupropion, which goes by Wellbutrin and other brand names, has fewer adverse sexual effects than Prozac, Zoloft, Paxil or Lexapro (escitalopram).

"If a patient has insomnia, you would pick something more immediately sedating," said Schlager, who is also a psychiatrist with Lone Star Circle of Care in Austin. "If the patient has decreased appetite and weight loss, you would pick something more likely to cause weight gain like mirtazapine."

Cost, of course, is another consideration.

"If one drug costs $200 a month and another costs $20, I don't see any reason why not to go with the latter," said Dr. Radu Saveanu, a professor of psychiatry at the University of Miami Miller School of Medicine.

Dosing is also important, he said, "because studies have shown that if patients have to take the drug less frequently, compliance is higher, which will make a big difference in terms of efficacy."

But given the similarity in effectiveness, prescribing antidepressants is still largely a trial-and-error process.

It's hoped that the next series of studies will provide guidance on which medications to try first.

"The real heart of the matter is, if they don't respond to one type of antidepressant, is there any guidelines about what you should try next?" Schlager said.

More information

The U.S. National Library of Medicine has more on antidepressants.

SOURCES: Radu V. Saveanu, M.D., professor, psychiatry, University of Miami Miller School of Medicine; David Schlager, M.D., clinical assistant professor, psychiatry and behavioral science, Texas A&M Health Science Center College of Medicine, and psychiatrist, Lone Star Circle of Care, Austin; Dec. 6, 2011, Annals of Internal Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Antidepressant linked to developmental brain abnormalities in rodents
2. Antidepressant Use Skyrocketed in Past 20 Years: CDC
3. Certain Antidepressants With Blood Thinners May Pose Risk for Heart Patients
4. Screen finds an antidepressant and other drugs
5. Fear of Antidepressants Keep Many From Disclosing Depression
6. Antidepressant Tied to Dangerous Heart Rhythm: FDA
7. Antidepressant Tied to Dangerous Heart Rhythm, FDA Says
8. Americans Use of Antidepressants On the Rise: Study
9. Certain Antidepressants Linked to Falls in Nursing Homes
10. Two Antidepressants Given to Dementia Patients Ineffective: Study
11. Research reveals that 10 percent of middle-aged Europeans are on antidepressants
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Best Antidepressant May Depend on Patient: Study
(Date:7/21/2017)... CA (PRWEB) , ... July 21, 2017 , ... West ... “Tu” Tuantu Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West ... 27 years of experience in dermatology, skin cancer , and more. She graduated ...
(Date:7/20/2017)... ... July 20, 2017 , ... TransPixel Volume 2 is a set of transitions ... timeline. This effect isolates horizontal and vertical lines of pixels and sorts their pixels ... or flipping animation and can be changed using a drop-down menu. Create amazing and ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... firm headquartered in Houston, is pleased to announce their expansion to the Midwest ... housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John Peck ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network of medical ... , directed by Dr. Russell Horine, DC to their exclusive list of medical professionals. ... Russell Horine serving as the clinic director and his son Dr. Lee Horine and ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced ... Dunbar received his BS in Biology from LSU, graduating summa cum laude. He attended ... President. After his residency in St. Louis, Dr. Dunbar moved to New York to ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology: